Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries ARS Pharmaceuticals, Inc. - Common Stock (NQ: SPRY ) 9.090 +0.430 (+4.97%) Streaming Delayed Price Updated: 1:00 PM EDT, Jul 3, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Price and Volume Detailed Quote Volume 698,443 Open 8.770 Bid (Size) 9.000 (20) Ask (Size) 9.340 (1) Prev. Close 8.660 Today's Range 8.770 - 9.620 52wk Range 2.550 - 11.27 Shares Outstanding N/A Dividend Yield N/A Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year Top News More News ARS Pharmaceuticals Announces EURneffy (adrenaline nasal spray) Recommended for Approval by CHMP for Emergency Treatment of Allergic Reactions (anaphylaxis) June 28, 2024 From ARS Pharmaceuticals, Inc. Via GlobeNewswire SPRY Stock Earnings: ARS Pharmaceuticals Meets EPS for Q1 2024 May 09, 2024 SPRY stock results show that ARS Pharmaceuticals met analyst estimates for earnings per share the first quarter of 2024. Via InvestorPlace Performance YTD +62.90% +62.90% 1 Month +0.55% +0.55% 3 Month -3.30% -3.30% 6 Month +65.27% +65.27% 1 Year +40.06% +40.06% More News Read More ARS Pharmaceuticals Highlights neffy Regulatory Progress and Reports First Quarter 2024 Financial Results May 09, 2024 From ARS Pharmaceuticals, Inc. Via GlobeNewswire ARS Pharmaceuticals Submits Response for neffy® (epinephrine nasal spray) Marketing Authorization Application to EMA’s CHMP and Enters License Agreement with CSL Seqirus for Commercialization of neffy in Australia and New Zealand April 30, 2024 From ARS Pharmaceuticals, Inc. Via GlobeNewswire ARS Pharmaceuticals Submits Response to FDA Complete Response Letter for neffy® (Epinephrine Nasal Spray) April 03, 2024 From ARS Pharmaceuticals, Inc. Via GlobeNewswire Top 5 Health Care Stocks That May Plunge In March March 28, 2024 Via Benzinga SPRY Stock Earnings: ARS Pharmaceuticals Beats EPS for Q4 2023 March 21, 2024 Via InvestorPlace Wall Street Favorites: 3 Under-$10 Stocks with Strong Buy Ratings for March 2024 March 15, 2024 Via InvestorPlace ARS Pharmaceuticals Reviews Recent Clinical Updates and Commercial Opportunity at neffy® Investor Day March 07, 2024 From ARS Pharmaceuticals, Inc. Via GlobeNewswire ARS Pharmaceuticals to Participate in the Leerink Partners Global Biopharma Conference 2024 March 06, 2024 From ARS Pharmaceuticals, Inc. Via GlobeNewswire Allergic Reaction Focused ARS Pharmaceuticals' Lead Candidate Shows Efficacy In Skin Disorder February 26, 2024 Via Benzinga ARS Pharmaceuticals announces neffy® meets primary endpoints and shows rapid symptom control in Phase 2 urticaria clinical study February 26, 2024 From ARS Pharmaceuticals, Inc. Via GlobeNewswire ARS Pharmaceuticals to Host Virtual neffy® Investor Day on March 7, 2024 February 22, 2024 From ARS Pharmaceuticals, Inc. Via GlobeNewswire ARS Pharma Readies Data In Response To FDA's Rejection For Its EpiPen Alternative For Severe Allergic Reactions February 20, 2024 Via Benzinga Exposures Product Safety ARS Pharma Announces Favorable Topline Results from Repeat Dosing Study of neffy® (Epinephrine Nasal Spray) Under Nasal Allergen Challenge Conditions, Readies Data for Response to FDA’s Complete Response Letter February 20, 2024 From ARS Pharmaceuticals, Inc. Via GlobeNewswire ARS Pharmaceuticals to Present Positive Clinical Efficacy Data for neffy® (epinephrine nasal spray) at 2024 AAAAI Annual Meeting February 05, 2024 From ARS Pharmaceuticals, Inc. Via GlobeNewswire Big Stocks Moving Higher On Friday: Synaptics Reports Q1 Beat; Joins Lyft, Hologic, Blink Charging November 10, 2023 Via Benzinga Topics Stocks Exposures US Equities Why Wynn Resorts Shares Are Trading Lower By Around 8%? Here Are Other Stocks Moving In Friday's Mid-Day Session November 10, 2023 Via Benzinga ARS Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Business Updates November 09, 2023 From ARS Pharmaceuticals, Inc. Via GlobeNewswire ARS Pharmaceuticals Announces Presentation of Clinical Data Supporting neffy® (epinephrine nasal spray) for the Treatment of Allergic Reactions (Type I) including Anaphylaxis November 09, 2023 From ARS Pharmaceuticals, Inc. Via GlobeNewswire INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against ARS Pharmaceuticals, Inc. and Encourages Investors with Losses to Contact the Firm October 26, 2023 Via ACCESSWIRE NASDAQ:SPRY Investor Notice: Investigation over Potential Securities Laws Violations by ARS Pharmaceuticals, Inc. October 11, 2023 Via SBWire ARS Pharmaceuticals Announces Scheduling of a Type A Meeting with the U.S. FDA for neffy® (epinephrine nasal spray) October 06, 2023 From ARS Pharmaceuticals, Inc. Via GlobeNewswire Single and Repeat Dose Clinical Study of neffy (epinephrine nasal spray) Published in the Journal of Allergy and Clinical Immunology October 03, 2023 From ARS Pharmaceuticals, Inc. Via GlobeNewswire Why TD SYNNEX Shares Are Trading Lower By Over 5%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session September 26, 2023 Via Benzinga Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
